VivoSim Labs, Inc. VIVS
Set alert
At close · Nov 2
After hours · Nov 2, 7:35 PM ET
- YTD
- -91.53%
- 1 year
- -94.32%
- Open
- 0.1549
- Prev close
- 0.1546
- Mkt cap
- 2.54M
- Vol
- 532.57K
- Avg vol
- 2.69M
- EPS
- -4.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1499
- High
- 0.1595
News
-
1 week ago benzinga.com
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human…
1 week ago globenewswire.com
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials Patient-derived…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
-
3 weeks ago benzinga.com
Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use
The FDA’s new rule replaces the term "animal tests" with "nonclinical tests" across its regulatory framework, formally opening pathways for NAMs, including human cell-based tests such as those…
3 weeks ago globenewswire.com
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's…
1 month ago defenseworld.net
VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison
iSpecimen (NASDAQ: ISPC - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two…
1 month ago globenewswire.com
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities New data…
-
2 months ago benzinga.com
VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to
2 months ago globenewswire.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New cross-species capability is designed to help pharma…
2 months ago benzinga.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings of 23 cents per share and sales of $20.898 million. Other stocks gaining pre-market include…
2 months ago globenewswire.com
VivoSim Provides Financial and Listing Compliance Update
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models…
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
-
3 months ago benzinga.com
VivoSim Labs Announces First Commercial Sales In China For Its NAMkind Testing Services
, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening…
3 months ago globenewswire.com
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market Initial customer wins bring VivoSim's human-relevant liver and GI testing…
3 months ago benzinga.com
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million. Agape ATP (NASDAQ:ATPC) shares moved…
3 months ago benzinga.com
Why Is VivoSim Labs Stock Falling Thursday?
VivoSim Labs (VIVS) stock plunges over 25% on a $4M private placement priced at $0.85/share. Read about the dilutive offering.
-
3 months ago benzinga.com
VivoSim Labs Prices ~$4M Private Placement Of Common Stock, Pre-Funded Warrants At Combined Price Of $0.85/Share, Accompanying Warrant
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it…
3 months ago globenewswire.com
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models…
3 months ago benzinga.com
Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA,…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences…
3 months ago benzinga.com
Why Vivosim Labs Shares Are Rocketing on Wednesday?
VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.
-
3 months ago benzinga.com
VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue
3 months ago globenewswire.com
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
-
4 months ago benzinga.com
VivoSim Labs To Present Data Demonstrating Its 3D Human Tissue Models In Two Presentations At The European Society Of Toxicology Annual Conference
The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver toxicology testing, across a set…
4 months ago globenewswire.com
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,…
6 months ago globenewswire.com
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
6 months ago defenseworld.net
Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%
VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) was the target of a large decline in short interest in April. As of April 15th, there was short interest totaling 27,969 shares, a decline of 69.3%…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
7 months ago benzinga.com
VivoSim Labs Announces The Pricing Of Up To A $4M Best-Efforts Public Offering, With $3M Funded At An Initial Closing Of The Offering
VivoSim Labs, Inc. (NASDAQ:VIVS), (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the pricing of up to a $4…
7 months ago globenewswire.com
VivoSim Announces Pricing of up to a $4 Million Public Offering
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,…
7 months ago defenseworld.net
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies…
-
7 months ago benzinga.com
VivoSim Labs Announces Its NAMkind Liver, Intestine Models Validated For Predicting Toxicity, Side Effect Profiles Of Antibody Drug Conjugates
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology…
7 months ago globenewswire.com
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company…
7 months ago defenseworld.net
VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update
VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 32,826 shares, a drop of…
8 months ago globenewswire.com
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach…
8 months ago defenseworld.net
VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest
VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 87,870…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago globenewswire.com
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects Company produces thorough reference…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
9 months ago benzinga.com
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
9 months ago benzinga.com
Dow Falls Over 100 Points; Verizon Earnings Top Views
Dow Falls Over 100 Points; Verizon Earnings Top Views
-
9 months ago benzinga.com
Market-Moving News for January 30th
SNDK: 22% | Sandisk shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 guidance above estimates. CVX: -1% | Chevron Reports Earnings
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
9 months ago benzinga.com
Why SanDisk Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why SanDisk Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
-
9 months ago benzinga.com
VivoSim Labs Signs JCBio As Authorized Distributor In Korea, Tekon Biotech In China For NAMKind Toxicology Services In Liver, Small Intestine
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an…